Supernus has developed with its partners several products across various therapeutic areas that are either marketed, awaiting FDA approval or are in late stage development. They include:

Supernus has also entered into two partnerships to enrich its pipeline. Both partnerships focus on the development of differentiated CNS specialty products:

Afecta

• Supernus has formed a partnership with Afecta where Supernus has exclusive rights to Afecta's pipeline in CNS. Afecta uses molecular biology and genetics of diseases to create new indications and uses for known molecules.
  

Rune Healthcare

• Supernus has acquired worldwide rights to a product concept from Rune Healthcare that will be an NCE in the US and may also offer new indication opportunities for worldwide markets.